



Clinical trial results:

A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of GlaxoSmithKline Biologicals Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.

Summary

EudraCT number	2015-001030-16
Trial protocol	Outside EU/EEA
Global end of trial date	11 June 2015

Results information

Result version number	v2
This version publication date	14 October 2017
First version publication date	24 June 2016
Version creation reason	<ul style="list-style-type: none">• New data added to full data setNew data added to full data set

Trial information

Trial identification

Sponsor protocol code	205232
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02285777
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 June 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 March 2015
Global end of trial reached?	Yes
Global end of trial date	11 June 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the effectiveness of the MenABCWY vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity at 1:4 dilution using enc-hSBA at one month after the 3-dose series, when compared to a single dose of MenACWY.

Protection of trial subjects:

Standard immunization practices were observed and care was taken to administer the injection intramuscularly. As with all injectable vaccines, appropriate medical treatment and supervision was readily available in case of rare anaphylactic reactions following administration of the study vaccine. Epinephrine 1:1000 and diphenhydramine was available in case of any anaphylactic reactions. Care was taken to ensure that the vaccine is not injected into a blood vessel. The measures of safety used in this study are routine clinical procedures. They include a close vigilance for, and stringent reporting of, selected local and systemic adverse events routinely monitored in vaccine clinical studies as indicators of reactogenicity. The period of observation for AEs extends from the time the subject signs informed consent until he or she completes the final study visit (Visit Month 4) or terminates the study early (whichever comes first).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 December 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 189
Worldwide total number of subjects	189
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	81

Adolescents (12-17 years)	97
Adults (18-64 years)	11
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

An Interactive Response Technology (IRT) will be used in the study. At Month 6 Visit of the parent study, IRT will allocate the study vaccines (either MenABCWY or placebo) to the subject. Subjects will receive either a 3rd dose of MenABCWY or one dose of a placebo, depending on their assigned vaccine group in parent study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Blinding implementation details:

Trial is observer-blinded. Observer-blind means that during the course of study, the subject, the parents/guardians of the subjects and the study personnel responsible for the evaluation of any study endpoint (e.g. safety and reactogenicity) will be unaware which vaccine was administered. The vaccine preparation and administration will be done by designated medical personnel who will not participate in any of the clinical study evaluations.

Arms

Are arms mutually exclusive?	Yes
Arm title	MenABCWY

Arm description:

Subjects who received 2 doses of MenABCWY vaccine in the parent study, now receive a 3rd dose of MenABCWY vaccine in the current study.

Arm type	Experimental
Investigational medicinal product name	Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine
Investigational medicinal product code	MenABCWY
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of 0.5 millilitres

Arm title	MenACWY
------------------	---------

Arm description:

Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study, now receive 1 dose of placebo in the current study.

Arm type	Active comparator
Investigational medicinal product name	Saline solution
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of 0.5 millilitres

Number of subjects in period 1	MenABCWY	MenACWY
Started	95	94
Completed	90	91
Not completed	5	3
Consent withdrawn by subject	1	1
Lost to follow-up	4	2

Baseline characteristics

Reporting groups

Reporting group title	MenABCWY
Reporting group description:	
Subjects who received 2 doses of MenABCWY vaccine in the parent study, now receive a 3rd dose of MenABCWY vaccine in the current study.	
Reporting group title	MenACWY
Reporting group description:	
Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study, now receive 1 dose of placebo in the current study.	

Reporting group values	MenABCWY	MenACWY	Total
Number of subjects	95	94	189
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	36	45	81
Adolescents (12-17 years)	53	44	97
Adults (18-64 years)	6	5	11
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	12.8	12.4	
standard deviation	± 2.36	± 2.4	-
Gender categorical			
Units: Subjects			
Female	40	33	73
Male	55	61	116
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska native	0	2	2
Asian	1	0	1
Black or African American	16	21	37
Native Hawaiian or Other Pacific Islander	0	0	0
White	74	66	140
Other	4	5	9

End points

End points reporting groups

Reporting group title	MenABCWY
Reporting group description: Subjects who received 2 doses of MenABCWY vaccine in the parent study, now receive a 3rd dose of MenABCWY vaccine in the current study.	
Reporting group title	MenACWY
Reporting group description: Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study, now receive 1 dose of placebo in the current study.	

Primary: Percentages of subjects without bactericidal activity at 1:4 dilution against each US *Neisseria meningitidis* (N. meningitidis) serogroup B strain at 1 month after the 3-dose vaccination series

End point title	Percentages of subjects without bactericidal activity at 1:4 dilution against each US <i>Neisseria meningitidis</i> (N. meningitidis) serogroup B strain at 1 month after the 3-dose vaccination series
End point description: The effectiveness of three doses of MenABCWY vaccine when compared to one dose of MenACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains at 1 month after the 3-dose vaccination series was evaluated in terms of: the combined percentage of subjects without bactericidal activity at 1:4 dilution using the human Serum Bactericidal Assay (hSBA) against each strain in MenABCWY group and MenACWY group. The data provided is an average of the percentage of subjects without bactericidal activity at 1:4 dilution across all 110 strains. Analysis was performed on FAS-Effectiveness (Month 7), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, received a subject ID and vaccination, and who provided evaluable serum sample with enc-hSBA result for at least one endemic N. meningitidis serogroup B invasive disease strain at Month 7.	
End point type	Primary
End point timeframe: At Month 7 (1 month after the 3-dose vaccination series)	

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	93		
Units: Percentage				
number (not applicable)				
Combined Endemic US Serogroup B Strains	21.1	73.7		

Statistical analyses

Statistical analysis title	Vaccine Effectiveness at 1 month after Dose 3
Statistical analysis description: The Vaccine Effectiveness (VE) at 1 month after the 3-dose vaccination series for each strain is defined as [1 - (percentage of subjects without bactericidal activity at 1:4 dilution in MenABCWY	

group/percentage of subjects without bactericidal activity at 1:4 dilution in MenACWY group]] x 100. The combined VE across all strains was computed by mean of a generalized linear model.

Comparison groups	MenABCWY v MenACWY
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	other ^[1]
P-value	< 0.0001
Method	Generalized Linear Model
Parameter estimate	Vaccine Effectiveness
Point estimate	71
Confidence interval	
level	95 %
sides	2-sided
lower limit	69
upper limit	73

Notes:

[1] - In order to obtain the VE measure which is a measure based on the relative risk (RR), the BINOMIAL DISTRIBUTION and LOG LINK options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval.

Secondary: Number of subjects reporting any solicited local or systemic Adverse Events (AEs)

End point title	Number of subjects reporting any solicited local or systemic Adverse Events (AEs)
-----------------	---

End point description:

Number of subjects reporting any solicited local or systemic AEs from Day 1 (6 hours) to Day 7 after any meningococcal vaccination is reported.

Assessed solicited local symptoms were induration, erythema and pain. Assessed solicited general symptoms were fatigue, myalgia, arthralgia, headache, fever, chills and loss of appetite. Other solicited data included prevention of pain/fever and treatment of pain/fever. Any = occurrence of the symptom regardless of intensity grade.

The analysis was performed on the Safety Set (solicited AEs and other solicited reactions), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, and provided post-vaccination reactogenicity data.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (6 hours) to Day 7 after vaccination

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	90	87		
Units: Subjects				
Any (Vacc.1, N=90,87)	62	25		
Any Local Reactions (Vacc.1, N=90,87)	60	15		
Any Systemic Reactions (Vacc.1, N=90,87)	27	15		
Induration (mm) (Vacc.1, N=88,87)	6	0		
Erythema (mm) (Vacc.1, N=87,86)	6	0		
Pain (Vacc.1, N=88,87)	59	15		
Nausea (Vacc.1, N=87,87)	5	5		
Fatigue (Vacc.1, N=87,87)	14	11		
Myalgia (Vacc.1, N=87,85)	13	3		

Arthralgia (Vacc.1, N=86,85)	9	0		
Headache (Vacc.1, N=88,87)	13	9		
Fever (Vacc.1, N=90,85)	0	1		
Chills (Vacc.1, N=88,87)	2	3		
Loss of appetite (Vacc.1, N=88,87)	3	3		
Prevention of pain/fever (Vacc.1, N=85,84)	0	0		
Treatment of pain/fever (Vacc.1, N=85,84)	12	3		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited AEs

End point title	Number of subjects reporting any unsolicited AEs
End point description:	
<p>The number of subjects reporting unsolicited AEs after any vaccination is reported. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</p> <p>The analysis was performed on the Safety set (unsolicited AEs), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, and had post-vaccination unsolicited adverse event records.</p>	
End point type	Secondary
End point timeframe:	
Day 1 to Day 30 after any vaccination	

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	93		
Units: Subjects				
Any AEs	14	11		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any serious adverse events (SAEs), medically-attended AEs and AEs leading to premature withdrawal

End point title	Number of subjects reporting any serious adverse events (SAEs), medically-attended AEs and AEs leading to premature withdrawal
-----------------	--

End point description:

The number of subjects reporting any SAEs, medically-attended AEs and AEs leading to premature withdrawal during the entire study period is reported. SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

The analysis was performed on the Safety Set (overall).

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (from Day 0 up to Month 10)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	94		
Units: Subjects				
Any SAEs (N=93,93)	0	0		
Any Medically Attended AEs (N=93,93)	14	20		
Any AEs leading to premature withdrawal (N=95,94)	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of subjects without bactericidal activity at 1:4 dilution against each US N. meningitidis serogroup B strain at 4 months after the 3-dose vaccination series

End point title	Percentages of subjects without bactericidal activity at 1:4 dilution against each US N. meningitidis serogroup B strain at 4 months after the 3-dose vaccination series
-----------------	--

End point description:

The effectiveness of three doses of MenABCWY vaccine when compared to one dose of MenACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains at 4 months after the 3-dose vaccination series was evaluated in terms of: the combined percentage of subjects without bactericidal activity at 1:4 dilution using the hSBA against each strain in MenABCWY group and MenACWY group. The data provided is an average of the percentage of subjects without bactericidal activity at 1:4 dilution across all 110 strains.

Analysis was performed on FAS-Effectiveness (Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, received a subject ID and vaccination, and who provided evaluable serum sample with enc-hSBA result for at least one endemic N. meningitidis serogroup B invasive disease strain at Month 10.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 10 (4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	90	90		
Units: Percentage				
number (not applicable)				
Combined Endemic US Serogroup B Strains	33.9	69.9		

Statistical analyses

Statistical analysis title	Vaccine Effectiveness at 4 months after Dose 3
Statistical analysis description:	
The VE at 4 months after the 3-dose vaccination series for each strain is defined as $[1 - (\text{percentage of subjects without bactericidal activity at 1:4 dilution in MenABCWY group} / \text{percentage of subjects without bactericidal activity at 1:4 dilution in MenACWY group})] \times 100$. The combined VE across all strains was computed by mean of a generalized linear model.	
Comparison groups	MenABCWY v MenACWY
Number of subjects included in analysis	180
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001 [2]
Method	Generalized Linear Model
Parameter estimate	Vaccine Effectiveness
Point estimate	51
Confidence interval	
level	95 %
sides	2-sided
lower limit	48
upper limit	55

Notes:

[2] - In order to obtain the VE measure which is a measure based on the relative risk (RR), the BINOMIAL DISTRIBUTION and LOG LINK options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval.

Secondary: Percentages of subjects without bactericidal activity at 1:8 dilution against each US N. meningitidis serogroup B strain at 1 and 4 months after the 3-dose vaccination series

End point title	Percentages of subjects without bactericidal activity at 1:8 dilution against each US N. meningitidis serogroup B strain at 1 and 4 months after the 3-dose vaccination series
End point description:	
The effectiveness of three doses of MenABCWY vaccine when compared to one dose of MenACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains at 1 and 4 months after the 3-dose vaccination series were evaluated in terms of: the combined percentage of subjects without bactericidal activity at 1:8 dilution using the hSBA against each strain in MenABCWY group and MenACWY group. The data provided is an average of the percentage of subjects without bactericidal activity at 1:8 dilution across all 110 strains. Analysis was performed on FAS-Effectiveness (Month 7 and 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, received a subject ID and vaccination, and who provided evaluable serum sample with enc-hSBA result for at least one endemic N. meningitidis serogroup B invasive disease strain at Month 7 and 10.	
End point type	Secondary
End point timeframe:	
At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)	

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	93		
Units: Percentage				
number (not applicable)				
Combined Serogroup B Strains (Month 7) (N=93;93)	36.9	75.8		
Combined Serogroup B Strains (Month 10) (N=90;90)	60.3	79.6		

Statistical analyses

Statistical analysis title	Vaccine Effectiveness at 1 month after Dose 3
Statistical analysis description:	
The VE at 1 month after the 3-dose vaccination series for each strain is defined as $[1 - (\text{percentage of subjects without bactericidal activity at 1:8 dilution in MenABCWY group} / \text{percentage of subjects without bactericidal activity at 1:8 dilution in MenACWY group})] \times 100$. The combined VE across all strains was computed by mean of a generalized linear model.	
Comparison groups	MenABCWY v MenACWY
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001 ^[3]
Method	Generalized Linear Model
Parameter estimate	Vaccine Effectiveness
Point estimate	51
Confidence interval	
level	95 %
sides	2-sided
lower limit	48
upper limit	54

Notes:

[3] - In order to obtain the VE measure which is a measure based on the relative risk (RR), the BINOMIAL DISTRIBUTION and LOG LINK options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval.

Statistical analysis title	Vaccine Effectiveness at 4 months after Dose 3
Statistical analysis description:	
The VE at 4 months after the 3-dose vaccination series for each strain is defined as $[1 - (\text{percentage of subjects without bactericidal activity at 1:8 dilution in MenABCWY group} / \text{percentage of subjects without bactericidal activity at 1:8 dilution in MenACWY group})] \times 100$. The combined VE across all strains was computed by mean of a generalized linear model.	
Comparison groups	MenABCWY v MenACWY

Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001 ^[4]
Method	Generalized Linear Model
Parameter estimate	Vaccine Effectiveness
Point estimate	24
Confidence interval	
level	95 %
sides	2-sided
lower limit	20
upper limit	28

Notes:

[4] - In order to obtain the VE measure which is a measure based on the relative risk (RR), the BINOMIAL DISTRIBUTION and LOG LINK options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval.

Secondary: Percentages of US N. meningitidis serogroup B strains killed at 1:4 and 1:8 dilutions at 1 and 4 months after the 3-dose vaccination series

End point title	Percentages of US N. meningitidis serogroup B strains killed at 1:4 and 1:8 dilutions at 1 and 4 months after the 3-dose vaccination series
-----------------	---

End point description:

The mean percentage of US N. meningitidis serogroup B strains killed by each subject, at 1:4 and 1:8 dilutions before the 3-dose vaccination series, at Month 6 (PRE) and at 1 and 4 months after the 3-dose vaccination series (Month 7 and Month 10).

The analysis was performed on the FAS-Effectiveness (Month 6, Month 7 and Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, and provided evaluable serum sample with the enc-hSBA result for at least one endemic N. meningitidis serogroup B invasive disease strain before the 3-dose vaccination series (Month 6) and at one and four months after the 3-dose series (Month 7 and Month 10).

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 6 (before the 3-dose vaccination series) and at Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	93		
Units: Percentage				
arithmetic mean (standard deviation)				
1:4, PRE (N=93;93)	56.97 (± 18.134)	22.94 (± 17.764)		
1:4, Month 7 (N=93;93)	77.78 (± 10.041)	21.91 (± 16.885)		
1:4, Month 10 (N=90;90)	62.37 (± 15.976)	22.49 (± 17.094)		
1:8, PRE (N=93;93)	28.81 (± 17.086)	11.53 (± 11.705)		
1:8, Month 7 (N=93;93)	56.95 (± 14.389)	11.4 (± 11.266)		
1:8, Month 10 (N=90;90)	31.46 (± 19.434)	11.15 (± 10.774)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of subjects with enc-hSBA \geq 1:4 and enc-hSBA \geq 1:8 at 1 and 4 months after the 3-dose vaccination series

End point title	Percentages of subjects with enc-hSBA \geq 1:4 and enc-hSBA \geq 1:8 at 1 and 4 months after the 3-dose vaccination series
-----------------	--

End point description:

The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of percentages of subjects with enc-hSBA \geq 1:4 and enc-hSBA \geq 1:8 against four N. meningitidis serogroup B test strains (M14459, M07-0241084, 96217 and NZ98/254) at 1 and 4 months after the 3-dose vaccination series (Month 7 and Month 10).

The analysis was performed on the FAS-Immunogenicity (Month 7 and Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, and provided evaluable serum samples at one and four months post-third vaccination (Month 7 and Month 10) and whose immunogenicity assay result was available for at least one serogroup B test strain.

End point type	Secondary
----------------	-----------

End point timeframe:

At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	90		
Units: Percentage				
number (confidence interval 95%)				
M14459 (\geq 1:4, Month 7) (N=91;90)	98 (92.3 to 99.73)	12 (6.3 to 20.8)		
M14459 (\geq 1:4, Month 10) (N=87;90)	72 (61.8 to 81.5)	12 (6.3 to 20.8)		
M14459 (\geq 1:8, Month 7) (N=91;90)	67 (56.4 to 76.5)	2 (0.27 to 7.8)		
M14459 (\geq 1:8, Month 10) (N=87;90)	21 (12.7 to 30.7)	1 (0.03 to 6)		
M07-0241084 (\geq 1:4, Month 7) (N=90;85)	81 (71.5 to 88.6)	21 (13.1 to 31.4)		
M07-0241084 (\geq 1:4, Month 10) (N=79;78)	46 (34.3 to 57.2)	22 (13.2 to 32.6)		
M07-0241084 (\geq 1:8, Month 7) (N=90;85)	38 (27.8 to 48.6)	5 (1.3 to 11.6)		
M07-0241084 (\geq 1:8, Month 10) (N=79;78)	11 (5.3 to 20.5)	6 (2.1 to 14.3)		
96217 (\geq 1:4, Month 7) (N=89;88)	99 (93.9 to 99.97)	48 (37 to 58.6)		
96217 (\geq 1:4, Month 10) (N=87;88)	100 (95.8 to 100)	41 (30.5 to 51.9)		

96217 ($\geq 1:8$, Month 7) (N=89;88)	99 (93.9 to 99.97)	17 (9.9 to 26.6)		
96217 ($\geq 1:8$, Month 10) (N=87;88)	99 (93.8 to 99.97)	16 (9 to 25.2)		
NZ98/254 ($\geq 1:4$, Month 7) (N=84;87)	76 (65.7 to 84.8)	1 (0.03 to 6.2)		
NZ98/254 ($\geq 1:4$, Month 10) (N=80;83)	34 (23.6 to 45.2)	1 (0.03 to 6.5)		
NZ98/254 ($\geq 1:8$, Month 7) (N=84;87)	39 (28.8 to 50.5)	1 (0.03 to 6.2)		
NZ98/254 ($\geq 1:8$, Month 10) (N=80;83)	4 (0.8 to 10.6)	0 (0 to 4.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: HT-hSBA Geometric Mean Titers (GMTs) against the N. meningitidis serogroup B test strains

End point title	HT-hSBA Geometric Mean Titers (GMTs) against the N. meningitidis serogroup B test strains
-----------------	---

End point description:

The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs against four N. meningitidis serogroup B test strains (M14459, M07-0241084, 96217 and NZ98/254) after the 3-dose vaccination series.

The analysis was performed on the FAS-Immunogenicity (Month 7 and Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at one and four months post-third vaccination (Month 7 and Month 10) and whose immunogenicity assay result was available for at least one serogroup B test strain.

End point type	Secondary
----------------	-----------

End point timeframe:

At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	91		
Units: Titers				
geometric mean (confidence interval 95%)				
M14459, Month 7 (N=91;88)	23.12 (20 to 27)	1.1 (0.94 to 1.29)		
M14459, Month 10 (N=88;91)	3.93 (3.14 to 4.91)	1.18 (0.95 to 1.46)		
M07-0241084, Month 7 (N=89;90)	12.26 (9.59 to 16)	1.74 (1.37 to 2.2)		
M07-0241084, Month 10 (N=86;90)	3.04 (2.36 to 3.92)	1.68 (1.31 to 2.14)		
96217, Month 7 (N=90;87)	367.29 (277 to 486)	4.02 (3.03 to 5.32)		
96217, Month 10 (N=87;85)	142.06 (105 to 191)	3.32 (2.46 to 4.48)		

NZ98/254, Month 7 (N=89;89)	19.69 (16 to 24)	1.02 (0.85 to 1.23)		
NZ98/254, Month 10 (N=87;90)	3.75 (3.01 to 4.68)	1.04 (0.84 to 1.29)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains \geq Lower Limit of Quantitation (LLQ) at 1 month after the 3-dose vaccination series

End point title	Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains \geq Lower Limit of Quantitation (LLQ) at 1 month after the 3-dose vaccination series
-----------------	--

End point description:

The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of percentages of subjects with HT-hSBA titers \geq LLQ (≥ 5 , ≥ 8 , ≥ 16 , ≥ 32 , ≥ 64 , ≥ 128) against serogroup N. meningitidis B test strains (M14459, M07-0241084, 96217 and NZ98/254), at 1 month after the 3-dose vaccination series.

The analysis was performed on the FAS-Immunogenicity (Month 7), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at one month post-third vaccination (Month 7) and whose immunogenicity assay result was available for at least one serogroup B test strain.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 7 (1 month after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	90		
Units: Percentage				
number (confidence interval 95%)				
M14459, ≥ 5 (N=91;88)	95 (87.6 to 98.2)	1 (0.03 to 6.2)		
M14459, ≥ 8 (N=91;88)	90 (82.1 to 95.4)	1 (0.03 to 6.2)		
M14459, ≥ 16 (N=91;88)	71 (61 to 80.4)	1 (0.03 to 6.2)		
M14459, ≥ 32 (N=91;88)	34 (24.5 to 44.7)	1 (0.03 to 6.2)		
M14459, ≥ 64 (N=91;88)	11 (5.4 to 19.3)	0 (0 to 4.1)		
M14459, ≥ 128 (N=91;88)	3 (0.7 to 9.3)	0 (0 to 4.1)		
M07-0241084, ≥ 5 (N=89;90)	82 (72.5 to 89.4)	16 (8.8 to 24.7)		
M07-0241084, ≥ 8 (N=89;90)	67 (56.7 to 77)	12 (6.3 to 20.8)		
M07-0241084, ≥ 16 (N=89;90)	46 (35.4 to 57)	8 (3.2 to 15.4)		
M07-0241084, ≥ 32 (N=89;90)	20 (12.4 to 30.1)	3 (0.7 to 9.4)		

M07-0241084, ≥ 64 (N=89;90)	6 (1.8 to 12.6)	2 (0.27 to 7.8)		
M07-0241084, ≥ 128 (N=89;90)	0 (0 to 4.1)	0 (0 to 4)		
96217, ≥ 5 (N=90;87)	100 (96 to 100)	38 (27.7 to 49)		
96217, ≥ 8 (N=90;87)	100 (96 to 100)	37 (26.7 to 47.8)		
96217, ≥ 16 (N=90;87)	100 (96 to 100)	25 (16.6 to 35.7)		
96217, ≥ 32 (N=90;87)	100 (96 to 100)	15 (8.2 to 24.2)		
96217, ≥ 64 (N=90;87)	99 (94 to 99.97)	8 (3.3 to 15.9)		
96217, ≥ 128 (N=90;87)	93 (86.1 to 97.5)	3 (0.7 to 9.7)		
NZ98/254, ≥ 5 (N=89;89)	89 (80.3 to 94.5)	1 (0.03 to 6.1)		
NZ98/254, ≥ 8 (N=89;89)	79 (68.7 to 86.6)	1 (0.03 to 6.1)		
NZ98/254, ≥ 16 (N=89;89)	61 (49.7 to 70.9)	0 (0 to 4.1)		
NZ98/254, ≥ 32 (N=89;89)	37 (27.1 to 48)	0 (0 to 4.1)		
NZ98/254, ≥ 64 (N=89;89)	10 (4.7 to 18.3)	0 (0 to 4.1)		
NZ98/254, ≥ 128 (N=89;89)	4 (1.2 to 11.1)	0 (0 to 4.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains \geq LLQ at 4 months after the 3-dose vaccination series

End point title	Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains \geq LLQ at 4 months after the 3-dose vaccination series
-----------------	---

End point description:

The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of percentages of subjects with HT-hSBA titers \geq LLQ (≥ 5 , ≥ 8 , ≥ 16 , ≥ 32 , ≥ 64 , ≥ 128) against serogroup N. meningitidis B test strains (M14459, M07-0241084, 96217 and NZ98/254), at 4 months after the 3-dose vaccination series.

The analysis was performed on the FAS - Immunogenicity (Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at four months post-third vaccination (Month 10) and whose immunogenicity assay result was available for at least one serogroup B test strain.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 10 (4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	91		
Units: Percentage				
number (confidence interval 95%)				
M14459, ≥ 5 (N=88;91)	49 (38.1 to 59.8)	4 (1.2 to 10.9)		
M14459, ≥ 8 (N=88;91)	36 (26.4 to 47.3)	3 (0.7 to 9.3)		
M14459, ≥ 16 (N=88;91)	17 (9.9 to 26.6)	1 (0.03 to 6)		
M14459, ≥ 32 (N=88;91)	6 (1.9 to 12.8)	0 (0 to 4)		
M14459, ≥ 64 (N=88;91)	1 (0.03 to 6.2)	0 (0 to 4)		
M14459, ≥ 128 (N=88;91)	0 (0 to 4.1)	0 (0 to 4)		
M07-0241084, ≥ 5 (N=86;90)	38 (28.1 to 49.5)	17 (9.6 to 26)		
M07-0241084, ≥ 8 (N=86;90)	24 (15.8 to 34.9)	12 (6.3 to 20.8)		
M07-0241084, ≥ 16 (N=86;90)	9 (4.1 to 17.5)	9 (3.9 to 16.8)		
M07-0241084, ≥ 32 (N=86;90)	1 (0.03 to 6.3)	3 (0.7 to 9.4)		
M07-0241084, ≥ 64 (N=86;90)	1 (0.03 to 6.3)	2 (0.27 to 7.8)		
M07-0241084, ≥ 128 (N=86;90)	0 (0 to 4.2)	1 (0.03 to 6)		
96217, ≥ 5 (N=87;85)	99 (93.8 to 99.97)	35 (25.2 to 46.4)		
96217, ≥ 8 (N=87;85)	99 (93.8 to 99.97)	33 (23.1 to 44)		
96217, ≥ 16 (N=87;85)	98 (91.9 to 99.72)	21 (13.1 to 31.4)		
96217, ≥ 32 (N=87;85)	94 (87.1 to 98.1)	16 (9.3 to 26.1)		
96217, ≥ 64 (N=87;85)	85 (75.8 to 91.8)	6 (1.9 to 13.2)		
96217, ≥ 128 (N=87;85)	56 (45.3 to 66.9)	2 (0.29 to 8.2)		
NZ98/254, ≥ 5 (N=87;90)	44 (33.1 to 54.7)	1 (0.03 to 6)		
NZ98/254, ≥ 8 (N=87;90)	34 (24.6 to 45.4)	1 (0.03 to 6)		
NZ98/254, ≥ 16 (N=87;90)	16 (9.1 to 25.5)	0 (0 to 4)		
NZ98/254, ≥ 32 (N=87;90)	5 (1.3 to 11.4)	0 (0 to 4)		
NZ98/254, ≥ 64 (N=87;90)	2 (0.28 to 8.1)	0 (0 to 4)		
NZ98/254, ≥ 128 (N=87;90)	2 (0.28 to 8.1)	0 (0 to 4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series

End point title	Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series
-----------------	--

End point description:

The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains, at 1 and 4 months after the 3-dose vaccination series.

The four-fold titers rise is defined as: a) for subjects with pre-vaccination HT-hSBA titers < LLQ, post-vaccination HT-hSBA titers \geq 4 LLQ; b) for subjects with pre-vaccination HT-hSBA titers \geq LLQ, an increase of at least four times the pre-vaccination HT-hSBA titers.

The analysis was performed on the FAS-Immunogenicity (Month 7 and Month 10).

End point type	Secondary
----------------	-----------

End point timeframe:

At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[5]	0 ^[6]		
Units: Percentage				
number (confidence interval 95%)	(to)	(to)		

Notes:

[5] - The results will be updated when they become available.

[6] - The results will be updated when they become available.

Statistical analyses

No statistical analyses for this end point

Secondary: HT-hSBA GMTs against N. meningitidis serogroups A, C, W and Y

End point title	HT-hSBA GMTs against N. meningitidis serogroups A, C, W and Y
-----------------	---

End point description:

The immunogenicity of three doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs to serogroups A, C, W, and Y, at 1 and 4 months after the 3-dose vaccination series.

The analysis was performed on the FAS-Immunogenicity (Month 7 and Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at one and four months post-third vaccination (Month 7 and Month 10) and whose immunogenicity assay result was available for at least one serogroup A, C, W and Y test strain.

End point type	Secondary
----------------	-----------

End point timeframe:

At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	91		
Units: Titers				
geometric mean (confidence interval 95%)				
Men A, Month 7 (N=91;87)	127.92 (91 to 179)	3.37 (2.41 to 4.73)		

Men A, Month 10 (N=85;88)	36.5 (25 to 53)	2.73 (1.89 to 3.94)		
Men C, Month 7 (N=85;86)	521.64 (365 to 745)	18.34 (13 to 26)		
Men C, Month 10 (N=86;89)	291.19 (201 to 421)	15.4 (11 to 22)		
Men W, Month 7 (N=83;88)	424.8 (310 to 581)	40.22 (30 to 54)		
Men W, Month 10 (N=85;83)	147.4 (104 to 209)	23.01 (16 to 33)		
Men Y, Month 7 (N=91;88)	204.84 (142 to 296)	13.27 (9.21 to 19)		
Men Y, Month 10 (N=86;91)	83.42 (55 to 126)	11.85 (7.93 to 18)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y \geq LLQ at 1 month after the 3- dose vaccination series

End point title	Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y \geq LLQ at 1 month after the 3- dose vaccination series
-----------------	--

End point description:

The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers \geq LLQ (≥ 8 , ≥ 16 , ≥ 32 , ≥ 64 , ≥ 128) against serogroups A, C, W, Y, at 1 month after the 3-dose vaccination series.

The analysis was performed on the FAS-Immunogenicity (Month 7), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at one month post-third vaccination (Month 7) and whose immunogenicity assay result was available for at least one serogroup A, C, W and Y test strain.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 7 (1 month after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	88		
Units: Percentage				
number (confidence interval 95%)				
Men A, ≥ 8 (N=91;87)	98 (92.3 to 99.73)	30 (20.5 to 40.6)		
Men A, ≥ 16 (N=91;87)	98 (92.3 to 99.73)	26 (17.6 to 37)		
Men A, ≥ 32 (N=91;87)	98 (92.3 to 99.73)	22 (13.7 to 32)		
Men A, ≥ 64 (N=91;87)	86 (76.8 to 92.2)	13 (6.5 to 21.5)		
Men A, ≥ 128 (N=91;87)	56 (45.2 to 66.4)	8 (3.3 to 15.9)		

Men C, ≥ 8 (N=85;86)	100 (95.8 to 100)	71 (60.1 to 80.2)		
Men C, ≥ 16 (N=85;86)	99 (93.6 to 99.97)	51 (40.1 to 62.1)		
Men C, ≥ 32 (N=85;86)	99 (93.6 to 99.97)	33 (22.8 to 43.5)		
Men C, ≥ 64 (N=85;86)	99 (93.6 to 99.97)	26 (16.8 to 36.1)		
Men C, ≥ 128 (N=85;86)	91 (82.3 to 95.8)	19 (11 to 28.4)		
Men W, ≥ 8 (N=83;88)	100 (95.7 to 100)	86 (77.4 to 92.8)		
Men W, ≥ 16 (N=83;88)	100 (95.7 to 100)	77 (67.1 to 85.5)		
Men W, ≥ 32 (N=83;88)	99 (93.5 to 99.97)	61 (50.4 to 71.6)		
Men W, ≥ 64 (N=83;88)	99 (93.5 to 99.97)	45 (34.8 to 56.4)		
Men W, ≥ 128 (N=83;88)	89 (80.4 to 94.9)	24 (15.4 to 34.1)		
Men Y, ≥ 8 (N=91;88)	100 (96 to 100)	61 (50.4 to 71.6)		
Men Y, ≥ 16 (N=91;88)	100 (96 to 100)	56 (44.7 to 66.3)		
Men Y, ≥ 32 (N=91;88)	95 (87.6 to 98.2)	44 (33.7 to 55.3)		
Men Y, ≥ 64 (N=91;88)	81 (71.8 to 88.7)	27 (18.3 to 37.8)		
Men Y, ≥ 128 (N=91;88)	65 (54.1 to 74.6)	14 (7.2 to 22.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y \geq LLQ at 4 months after the 3-dose vaccination series

End point title	Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y \geq LLQ at 4 months after the 3-dose vaccination series
-----------------	--

End point description:

The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers \geq LLQ (≥ 8 , ≥ 16 , ≥ 32 , ≥ 64 , ≥ 128) against serogroups A, C, W, Y, at 4 months after the 3-dose vaccination series.

The analysis was performed on the FAS-Immunogenicity (Month 10), which included all screened subjects who provided informed consent and demographic and/or baseline screening assessments, regardless of the subject's assignment and treatment status in the study, received a subject ID and a study vaccination, provided evaluable serum samples at four months post-third vaccination (Month 10) and whose immunogenicity assay result was available for at least one serogroup A, C, W and Y test strain.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 10 (4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86	91		
Units: Percentage				
number (confidence interval 95%)				
Men A, ≥ 8 (N=85;88)	86 (76.6 to 92.5)	25 (16.4 to 35.4)		
Men A, ≥ 16 (N=85;88)	84 (73.9 to 90.7)	23 (14.5 to 32.9)		
Men A, ≥ 32 (N=85;88)	72 (61 to 81)	18 (10.8 to 27.8)		
Men A, ≥ 64 (N=85;88)	46 (35 to 57)	8 (3.3 to 15.7)		
Men A, ≥ 128 (N=85;88)	14 (7.5 to 23.4)	7 (2.5 to 14.3)		
Men C, ≥ 8 (N=86;89)	100 (95.8 to 100)	65 (54.3 to 75)		
Men C, ≥ 16 (N=86;89)	98 (91.9 to 99.72)	48 (37.6 to 59.2)		
Men C, ≥ 32 (N=86;89)	97 (90.1 to 99.3)	34 (24 to 44.5)		
Men C, ≥ 64 (N=86;89)	86 (76.9 to 92.6)	26 (17.1 to 36.2)		
Men C, ≥ 128 (N=86;89)	74 (63.9 to 83.2)	16 (8.9 to 25)		
Men W, ≥ 8 (N=85;83)	99 (93.6 to 99.97)	75 (64 to 83.6)		
Men W, ≥ 16 (N=85;83)	98 (91.8 to 99.71)	66 (55.1 to 76.3)		
Men W, ≥ 32 (N=85;83)	94 (86.8 to 98.1)	58 (46.5 to 68.6)		
Men W, ≥ 64 (N=85;83)	75 (64.7 to 84)	36 (25.9 to 47.4)		
Men W, ≥ 128 (N=85;83)	52 (40.7 to 62.7)	18 (10.5 to 28)		
Men Y, ≥ 8 (N=86;91)	91 (82.5 to 95.9)	58 (47.4 to 68.5)		
Men Y, ≥ 16 (N=86;91)	86 (76.9 to 92.6)	51 (39.9 to 61.2)		
Men Y, ≥ 32 (N=86;91)	77 (66.4 to 85.2)	38 (28.4 to 49.2)		
Men Y, ≥ 64 (N=86;91)	62 (50.5 to 71.9)	20 (12.2 to 29.4)		
Men Y, ≥ 128 (N=86;91)	40 (29.2 to 50.7)	9 (3.9 to 16.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series

End point title	Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series
-----------------	--

End point description:

The immunogenicity of three doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with two-, three- and four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains, at 1 and 4 months after the 3-dose vaccination series. The four-fold titers rise is defined as: a) for subjects with pre-vaccination HT-hSBA titers < LLQ, a post-vaccination HT-hSBA titers ≥ 4 LLQ; b) for subjects with pre-vaccination HT-hSBA titers \geq LLQ, an increase of at least four times the pre-vaccination HT-hSBA titers.

The analysis was performed on the FAS - Immunogenicity (Month 7 and Month 10).

End point type	Secondary
----------------	-----------

End point timeframe:

At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

End point values	MenABCWY	MenACWY		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[7]	0 ^[8]		
Units: Percentage				
number (confidence interval 95%)	(to)	(to)		

Notes:

[7] - The results will be updated when they become available.

[8] - The results will be updated when they become available.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited local and general symptoms: from Day 1 to Day 7. Unsolicited AEs: from Day 1 to Day 30. SAEs, medically-attended AEs and AEs leading to withdrawal: for the entire duration of the study (from Day 0 to Month 10).

Adverse event reporting additional description:

Data are presented in terms of number of subjects reporting AEs.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.1
--------------------	------

Reporting groups

Reporting group title	MenABCWY
-----------------------	----------

Reporting group description:

Subjects who received 2 doses of MenABCWY vaccine in the parent study, now receive the 3rd dose of MenABCWY vaccine in the current study.

Reporting group title	MenACWY
-----------------------	---------

Reporting group description:

Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study, now receive 1 dose of placebo in the current study.

Serious adverse events	MenABCWY	MenACWY	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 95 (0.00%)	0 / 94 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	MenABCWY	MenACWY	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	67 / 95 (70.53%)	42 / 94 (44.68%)	
Nervous system disorders			
Headache			
subjects affected / exposed ^[1]	14 / 93 (15.05%)	9 / 93 (9.68%)	
occurrences (all)	25	27	
General disorders and administration site conditions			

Fatigue subjects affected / exposed ^[2] occurrences (all)	14 / 93 (15.05%) 32	11 / 93 (11.83%) 24	
Injection site erythema subjects affected / exposed ^[3] occurrences (all)	16 / 93 (17.20%) 44	4 / 93 (4.30%) 12	
Injection site induration subjects affected / exposed ^[4] occurrences (all)	16 / 93 (17.20%) 57	3 / 93 (3.23%) 10	
Injection site pain subjects affected / exposed ^[5] occurrences (all)	60 / 93 (64.52%) 155	15 / 93 (16.13%) 23	
Gastrointestinal disorders Nausea subjects affected / exposed ^[6] occurrences (all)	5 / 93 (5.38%) 9	5 / 93 (5.38%) 7	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed ^[7] occurrences (all) Myalgia subjects affected / exposed ^[8] occurrences (all)	9 / 93 (9.68%) 21 13 / 93 (13.98%) 33	1 / 93 (1.08%) 1 3 / 93 (3.23%) 10	
Infections and infestations Upper respiratory tract infection subjects affected / exposed ^[9] occurrences (all)	6 / 93 (6.45%) 6	1 / 93 (1.08%) 1	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom

sheets completed.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Exposed set, only on subjects with their symptom sheets completed.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported